ALXO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
18.0M
-4.9%
19.0M
-17.6%
23.0M
+2.2%
22.5M
-15.4%
26.6M
R&D
13.1M
-3.4%
13.6M
-22.9%
17.6M
+1.2%
17.4M
-3.2%
18.0M
SG&A
5.1M
-4.2%
5.4M
-0.3%
5.4M
+5.6%
5.1M
-6.6%
5.5M
Operating Income
-18033000
+4.9%
-18966000
+17.6%
-23021000
-2.2%
-22532000
+15.4%
-26648000
EBITDA
-18185000
+3.4%
-18816000
+17.7%
-22870000
-2.2%
-22379000
+3.9%
-23282000
Net Income
-17971000
-0.2%
-17927000
+21.5%
-22848000
-3.2%
-22144000
+14.7%
-25949000
EPS (Basic)
$-0.13
+23.5%
$-0.17
+59.5%
$-0.42
-2.4%
$-0.41
+16.3%
$-0.49
EPS (Diluted)
$-0.13
+23.5%
$-0.17
+59.5%
$-0.42
-2.4%
$-0.41
+16.3%
$-0.49
Shares (Diluted)
135.6M
+29.7%
104.6M
+92.8%
54.3M
+1.3%
53.6M
+0.2%
53.4M
ALX Oncology (ALXO) โ€” Financials